Hyundai Bioscience, a leading biotechnology company, has revealed its plans for clinical trials targeting cancer patients with intractable cancer caused by p53 gene mutations. The p53 gene, known as the “guardian of the genome,” plays a critical role in detecting DNA damage and inducing cell death. However, mutations in this gene can lead to resistance to existing anti-cancer drugs and the rapid spread of cancer cells.
In a groundbreaking development, Hyundai Bioscience has developed an oral anticancer drug called “Niclosamide Metabolic Anticancer Drug” that specifically targets cancer cells with p53 gene mutations. This drug has the potential to selectively kill mutated cancer cells without harming normal cells, offering hope for patients with limited treatment options.
Niclosamide, although previously overlooked for its potential as an anticancer agent, has shown promise in inducing cancer cell death by regulating metabolic pathways. Additionally, it can overcome drug resistance and inhibit the metastasis of cancer cells. When used in combination with existing anticancer drugs, Niclosamide has demonstrated enhanced effectiveness.
The challenge in developing Niclosamide as an anticancer drug has been its low bioavailability and short half-life. However, Hyundai Bioscience’s patented drug delivery system technology has overcome these obstacles and successfully developed Niclosamide as an oral anticancer agent. This formulation reaches the necessary drug concentration level to inhibit the proliferation of most cancer cells at a non-toxic dose.
In recent in vivo studies on triple-negative breast cancer, Hyundai Bioscience conducted combination therapy using the oral Niclosamide-based anticancer agent and the commonly used chemotherapeutic drug, docetaxel. The results showed a 67% higher anticancer effect compared to the group treated with docetaxel alone. Animal toxicity tests also confirmed the drug’s safety profile at therapeutic concentrations.
CEO of Hyundai Bioscience, Sang-ki Oh, expressed his optimism about the potential for Niclosamide as a selective p53-targeting anticancer treatment. He further announced that Hyundai Bioscience’s subsidiary, ADM Korea, will conduct clinical trials on cancer patients with p53 mutations as the first step in the clinical development of the Niclosamide-based anticancer agent pipeline.
Jong-Eon Lim, CEO of ADM Korea, stated that the company plans to submit an IND (Investigational New Drug) for a clinical trial that will compare combination therapy with the Niclosamide-based anticancer drug and existing anticancer drugs against single-agent therapy. This trial aims to advance Hyundai Bioscience into a specialized biotech company focused on oral metabolic anticancer agents.
Hyundai Bioscience’s dedication to advancing cancer treatment through targeted therapies brings hope to patients with intractable cancer caused by p53 gene mutations. With their innovative approach and promising results, the future of anticancer treatments looks brighter than ever.
About Hyundai Bioscience:
Established in 2000, Hyundai Bioscience is a biotechnology company specializing in the development of new drugs using its proprietary drug delivery system technologies. With a focus on repurposing and expanding indications of existing drugs, Hyundai Bioscience aims to deliver active ingredients safely and efficiently to targeted areas of the human body. The company is listed on KOSDAQ (symbol: 048410) in South Korea.
For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]).
SOURCE Hyundai Bioscience
Hyundai Bioscience’s announcement of clinical trials for targeting cancer patients with p53 gene mutations is a significant development in the field of oncology. This breakthrough could potentially provide a viable treatment option for patients with intractable cancer caused by p53 gene mutations, who currently have limited treatment options.
The p53 gene is known as the “guardian of the genome” due to its crucial role in detecting DNA damage and inducing cell death. However, mutations in this gene can lead to the resistance of existing anti-cancer drugs and the rapid spread of cancer cells. By specifically targeting cancer cells with p53 gene mutations, Hyundai Bioscience’s oral anticancer drug, “Niclosamide Metabolic Anticancer Drug,” has the potential to selectively kill mutated cancer cells while sparing normal cells.
Niclosamide, previously overlooked for its anticancer potential, has shown promise in inducing cancer cell death by regulating metabolic pathways. It also demonstrates the ability to overcome drug resistance and inhibit the metastasis of cancer cells. When used in combination with existing anticancer drugs, Niclosamide has shown enhanced effectiveness.
One challenge in developing Niclosamide as an anticancer drug has been its low bioavailability and short half-life. However, Hyundai Bioscience’s patented drug delivery system technology has overcome this obstacle and successfully developed Niclosamide as an oral anticancer agent. This formulation reaches the necessary drug concentration level to inhibit cancer cell proliferation at a non-toxic dose.
Recent in vivo studies on triple-negative breast cancer have shown the potential of Niclosamide. Combination therapy using the oral Niclosamide-based anticancer agent and the commonly used chemotherapeutic drug, docetaxel, demonstrated a 67% higher anticancer effect compared to docetaxel alone. Animal toxicity tests also confirmed the drug’s safety profile at therapeutic concentrations.
Hyundai Bioscience’s subsidiary, ADM Korea, will conduct clinical trials on cancer patients with p53 mutations, marking a crucial step in the clinical development of the Niclosamide-based anticancer agent pipeline. These trials intend to compare combination therapy with the Niclosamide-based drug against single-agent therapy using existing anticancer drugs.
Advantages of Hyundai Bioscience’s approach include the potential for selective targeting of cancer cells with p53 gene mutations, the ability to overcome drug resistance, and the enhanced efficacy when used in combination therapy. The development of an oral, non-toxic formulation of Niclosamide also provides an advantage in terms of patient compliance and safety.
However, there are potential challenges and controversies associated with this subject. One challenge is the need for further clinical trials to validate the effectiveness and safety of the Niclosamide-based anticancer agent. Additionally, the cost and accessibility of this targeted therapy may pose challenges to widespread adoption, especially in healthcare systems with limited resources.
In summary, Hyundai Bioscience’s clinical trials targeting cancer patients with p53 gene mutations offer hope for those with limited treatment options. The development of a selective and effective anticancer agent like Niclosamide demonstrates the potential to improve outcomes for patients with intractable cancer. With further research and successful clinical trials, Hyundai Bioscience could contribute significantly to the field of oncology.
For more information, please visit Hyundai Bioscience.